Corvus Pharmaceuticals Inc (NASDAQ:CRVS) CFO Leiv Lea Purchases 15,500 Shares

Corvus Pharmaceuticals Inc (NASDAQ:CRVS) CFO Leiv Lea purchased 15,500 shares of the business’s stock in a transaction on Thursday, June 6th. The shares were purchased at an average cost of $3.56 per share, for a total transaction of $55,180.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.

NASDAQ:CRVS opened at $3.66 on Tuesday. The company has a quick ratio of 12.39, a current ratio of 12.39 and a debt-to-equity ratio of 0.03. Corvus Pharmaceuticals Inc has a 12-month low of $3.22 and a 12-month high of $13.91.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its earnings results on Thursday, May 9th. The company reported ($0.40) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.40). As a group, sell-side analysts predict that Corvus Pharmaceuticals Inc will post -1.61 earnings per share for the current fiscal year.



CRVS has been the topic of several research analyst reports. Zacks Investment Research raised Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research report on Monday, February 11th. Wedbush cut their price target on Corvus Pharmaceuticals from $19.00 to $11.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 13th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $9.19.

Several large investors have recently added to or reduced their stakes in the company. Prudential Financial Inc. increased its holdings in shares of Corvus Pharmaceuticals by 15.0% in the fourth quarter. Prudential Financial Inc. now owns 21,545 shares of the company’s stock valued at $79,000 after purchasing an additional 2,805 shares during the period. State of Wisconsin Investment Board increased its holdings in shares of Corvus Pharmaceuticals by 29.4% in the first quarter. State of Wisconsin Investment Board now owns 18,500 shares of the company’s stock valued at $74,000 after purchasing an additional 4,200 shares during the period. Rhumbline Advisers increased its holdings in shares of Corvus Pharmaceuticals by 44.1% in the fourth quarter. Rhumbline Advisers now owns 18,203 shares of the company’s stock valued at $67,000 after purchasing an additional 5,570 shares during the period. Acadian Asset Management LLC increased its holdings in shares of Corvus Pharmaceuticals by 23.9% in the first quarter. Acadian Asset Management LLC now owns 42,394 shares of the company’s stock valued at $170,000 after purchasing an additional 8,165 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Corvus Pharmaceuticals by 18.3% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 58,951 shares of the company’s stock valued at $237,000 after purchasing an additional 9,101 shares during the period. 84.46% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Corvus Pharmaceuticals Inc (NASDAQ:CRVS) CFO Leiv Lea Purchases 15,500 Shares” was originally published by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://dakotafinancialnews.com/2019/06/11/corvus-pharmaceuticals-inc-nasdaqcrvs-cfo-leiv-lea-purchases-15500-shares.html.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

Further Reading: How do investors use RSI to grade stocks?

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.